Challenges to HIV prevention--seeking effective measures in the absence of a vaccine.

摘要

HIV-prevention trials also lack reliable surrogate end points for HIV infection or product activity and must therefore use HIV infection as the end point. Thus, effectiveness trials cannot be preceded by smaller studies using surrogate end points to demonstrate proof of concept and efficacy under ideal circumstances. As a result, such studies need to be large and sometimes lengthy, making them both costly and challenging.